Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 84.3%

Neg 84.3% Neu 0% Pos 0%

Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.5 to $2.